Testing ALN-4324 effects on insulin response in adults with type 2 diabetes
Compares one dose of ALN-4324 against placebo in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
Key facts
- Where
- Chula Vista, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07465224, who can take part
Where in United States
- Chula VistaChula Vista, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alnylam Pharmaceuticals
- Trial code
- NCT07465224
- Record updated
- 20 October 2026
- Original description
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DMRead full original descriptionShow less
A Randomized, Double-blind, Placebo-controlled Study Investigating the Effect of ALN-4324 on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
Inclusion: Is an adult patient with a confirmed diagnosis of T2DM; Has a body mass index (BMI) of ≥23 kg/m\^2 to ≤39.9 kg/m\^2; Has a hemoglobin A1c (HbA1c) ≥6.5% to <10.5%; Is on a stable dose of metformin, sodium-glucose cotransporter 2 inhibitor (SGLT2i), or dipeptidyl peptidase-4 inhibitor (DPP4i).
Exclusion: Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results; Receiving therapies known to interfere with glucose or insulin metabolism other than current treatment for T2DM or birth control methods; Note: other protocol defined inclusion/exclusion criteria apply.